Financial Performance - Revenue for the six months ended September 30, 2025, was HK$1,618,471,000, a decrease of 10.1% from HK$1,800,461,000 in the same period of 2024[4] - Gross profit for the same period was HK$487,638,000, down 13.0% from HK$560,423,000 year-over-year[4] - Profit for the period attributable to owners of the Company was HK$100,782,000, a decline of 15.6% compared to HK$119,398,000 in 2024[5] - Basic earnings per share decreased to 20.68 HK cents from 24.50 HK cents, reflecting a 15.4% drop[5] - Total comprehensive income for the period was HK$124,955,000, down 15.7% from HK$148,307,000 in the previous year[5] Cash and Assets - Cash and cash equivalents increased to HK$978,785,000 from HK$836,081,000, representing a growth of 17.0%[6] - Non-current assets totaled HK$636,452,000, an increase from HK$589,431,000 as of March 31, 2025[6] - Current liabilities rose to HK$464,386,000 from HK$346,991,000, indicating a significant increase of 33.8%[6] - Inventories decreased to HK$446,427,000 from HK$466,304,000, a reduction of 4.0%[6] - As of September 30, 2025, net current assets increased to HK$1,327,301, up from HK$1,307,091 as of March 31, 2025, reflecting a growth of approximately 1.6%[7] Equity and Dividends - Total equity reached HK$1,798,348, up from HK$1,754,782, representing an increase of approximately 2.5%[7] - The company declared a final dividend of HK$20,469,000 and a special dividend of HK$60,920,000 for the fiscal year 2025[8] - The company proposed an interim dividend of HK$25,830,000 and an interim special dividend of HK$75,541,000 for the fiscal year 2026[8] - The total equity attributable to owners of the company increased to HK$1,796,537,000 as of September 30, 2025, compared to HK$1,753,039,000 at the beginning of the period[8] Segment Performance - Segment revenue for Hong Kong decreased to HK$351,481,000 in 2025 from HK$423,882,000 in 2024, a decline of approximately 17%[28] - Segment revenue for The PRC was HK$1,261,103,000 in 2025, down from HK$1,322,763,000 in 2024, representing a decrease of about 5%[28] - Segment profit for The PRC increased to HK$218,149,000 in 2025 from HK$212,328,000 in 2024, a growth of approximately 3.7%[28] Operational Insights - The luxury sector has faced increasing pressure due to a shift in consumer spending towards experiences, travel, and wellness[137] - The Group's performance has been affected by cautious consumer spending patterns prioritizing daily necessities over luxury goods[137] - Watch exports to Chinese Mainland and Hong Kong declined by 16.3% and 8.3%, respectively, between January and September 2025[149] Employee and Governance - The Group had no bank loans as of September 30, 2025, resulting in a nil gearing ratio[151] - Approximately 64% of the Group's 570 employees were located in Chinese Mainland as of September 30, 2025[157] - The Company has adhered to the Corporate Governance Code throughout the reporting period, with a noted deviation regarding the separation of the roles of chairman and chief executive[165] Share Award Scheme - The group has a share award scheme valid for 10 years, aimed at motivating and retaining eligible employees and directors[90] - The total number of awards available for grant under the 2022 Share Award Scheme is 48,735,822 shares, representing 10% of the issued share capital of the Company as of the report date[94] - No share award has been granted under the 2022 Share Award Scheme since the Adoption Date[94]

目錄 2 簡明綜合損益及其他全面收益表 3 簡明綜合財務狀況表 5 簡明綜合權益變動表 6 簡明綜合現金流量表 7 簡明綜合財務報表附註 17 管理層討論及分析 21 其他資料 簡明綜合損益及其他全面收益表 截至2025年9月30日止六個月 （以港元列示） | | | 截至9月30日止六個月 | | | --- | --- | --- | --- | | | | 2025年 | 2024年 | | | 附註 | 千港元 | 千港元 | | | | （未經審核） | （未經審核） | | 收益 | 4 | 45,045 | 44,622 | | 銷售成本 | 5 | (24,754) | (24,234) | | 毛利 | | 20,291 | 20,388 | | 其他收入 | | 5 | 56 | | 分階段收購一間附屬公司之收益 | 11 | – | 1,499 | | 銷售及分銷開支 | 5 | (8,798) | (7,136) | | 行政開支 | 5 | (10,334) | (10,908) | | 經營溢利 | | 1,164 | 3,899 | | 財務收入 | | 387 | 687 | ...

香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司帶有較高 投資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決 定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受較大的市場波 動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不發表任何聲明， 並明確表示概不就因本報告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告包括的資料乃遵照聯交所的GEM證券上市規則（「GEM上市規則」）的規定而提供有關源想集團有限 公司（「本公司」）及其附屬公司（統稱「本集團」）的資料。本公司董事（「董事」）願就本報告共同及個別承擔 全部責任。董事在作出一切合理查詢後確認，就彼等所知及所信，本報告所載資料在各重大方面均屬準確 完整，且無誤導或欺騙成份，及本報告並無遺漏其他事項，致使本報告或當中所載任何陳述產生誤導。 1 源想集團有限公司 • 2025年中期報告 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 GUANGDONG – HONG KONG GREATER BAY AREA HOLDINGS LIMITED 除2014年年報所載資料外，本公司董事（「董事」）會（「董事會」）謹此提供以下補 充資料。 根據上市規則附錄D2第24段（或當時上市規則附錄16），本公司謹此提供有關本 公司前任行政總裁王德文先生（「王先生」）截至2014年12月31日止年度薪酬的補 充資料。王德文先生於2014年5月13日獲委任為本公司行政總裁，於2015年1月 26日獲委任為本公司執行董事，並已於2022年辭任行政總裁及執行董事。 1 據董事作出一切合理查詢後所知、所悉及所信，王先生於截至2014年12月31日止 年度的薪酬如下： 以權益結算 薪金、津貼 退休計劃 以股份為基 粵港灣控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1396） 與截至2014年12月31日止年度的年度報告有關的補充公告 茲提述粵港 ...

Love The Community Serve The Better 服務美好 、善愛生活 Annual Report 2024 年報 Annual Report 2024 年報 OPERATION is the Key REPUTATION Comes First Service provider for the community and industry 社區運營服務商、產業運營服務商 BUSINESS MOTTO 經營理念 Surpassing Customers' Expectation and Creating Values with Quality Services 超越客戶期待、 服務創造價值 Leading Property Management Enterprise in the Yangtze River Delta Megalopolis 運營為王 口碑至上 長三角領先物管企業 BUSINESS MODEL 業務模式 Service alignment, Business modularisation, Modules specialisation and Management di ...

Serve The Better Love The Community 服務美好 、善愛生活 Interim Report 2024 中期報告 Interim Report 2024 中期報告 CONTENT 目錄 | 2 | Company Introduction | 28 | Interim Condensed Consolidated Statement | | --- | --- | --- | --- | | | 公司簡介 | | of Profit or Loss and Other Comprehensive Income | | | | | 中期簡明綜合損益及其他全面收益表 | | 3 | Corporate Information | | | | | 公司資料 | 30 | Interim Condensed Consolidated Statement of | | | | | Financial Position | | 5 | Management Discussion and Analysis | | 中期簡明綜合財務狀況表 | | | 管理層討論與分析 | | | | | | 3 ...

Revenue Performance - Medical products revenue for the fiscal year 2024 reached HKD 25.57 million, a 16.5% increase from HKD 21.94 million in fiscal year 2023[5] - Custom components for medical equipment saw a significant revenue increase of 86%, driven by a shift towards comprehensive systems like Continuous Glucose Monitoring (CGM)[8] - Sales of blood collection tubes and equipment dropped from HKD 30.43 million in fiscal year 2022 to HKD 14.13 million in fiscal year 2023, a decline of 53.6%[7] - Revenue from pandemic-related products fell to zero in fiscal year 2023, a 100% decrease from HKD 16.34 million in fiscal year 2022, due to normalized demand post-COVID-19[6] Product Development and Expansion - The company plans to expand its product offerings to include surgical instruments, orthopedic tools, imaging equipment, and disinfection products[11] - The company intends to launch 2 to 3 new co-developed products by 2026, including surgical instrument kits and imaging equipment accessories[14] - The newly obtained production license is a strategic expansion of the existing medical business segment, significantly broadening the product portfolio with new devices and components, including infusion and transfusion devices, nursing and care equipment, and protective gear[15] - The production license allows the company to market and sell a diverse range of medical devices in China, covering categories such as active and passive surgical instruments, orthopedic surgical instruments, medical imaging equipment, and more[16] Regulatory Compliance and Quality Control - The company is focusing on diversifying its product lines while ensuring regulatory compliance with certifications like CE and FDA[11] - The company emphasizes compliance with strict quality and regulatory standards to ensure the highest levels of safety and effectiveness for its medical products[28] - The production facilities have received FDA certification, reflecting the company's commitment to adhering to strict regulatory frameworks[28] - The company emphasizes strict quality control and regulatory compliance in all operations, whether internal or outsourced[30] Market Strategy and Partnerships - The company aims to achieve product registration and distribution permits in Shandong by August 2025, marking a significant milestone for market entry[12] - The company is actively seeking partnerships with subcontractors that have existing certifications to expedite market entry without significant capital expenditure[12] - The company anticipates obtaining additional provincial registrations in China by the fourth quarter of 2026 to expand its geographical coverage[13] - The company will adopt a data-driven regional expansion strategy to optimize service delivery and enhance commitment to hospital clients[34] Operational Capacity and Team - The company has established an 8-member dedicated operations team led by Mr. Dai Zhongliang, who has over ten years of experience in the medical products industry, to manage and monitor all manufacturing processes[27] - The company has a maximum annual production capacity of approximately 5 million units at its existing facility in Dongguan, China[31] - The business model under the production license remains unchanged, ensuring rapid expansion of the product range while maintaining effective operational strategies[17] Financial Projections and Market Outlook - The Chinese healthcare market is projected to grow at a compound annual growth rate of approximately 12-14%, reaching over $250 billion by 2030[32] - The company plans to achieve estimated sales of RMB 20 million by December 2025 through strategic partnerships with clients introduced by a new management team member[33] - The board is optimistic about business prospects due to strong market demand and strategic initiatives taken[32] - The establishment of a new subsidiary in Jinan, Shandong, aims to strengthen the company's market presence in China[33] Customer Engagement and Sales Strategy - The sales and marketing department is tasked with customer engagement, handling inquiries, and coordinating sales orders to ensure timely processing and delivery[23] - The company aims to enhance its core business by providing a more comprehensive product suite to meet broader customer needs and generate additional revenue streams[15] - The company will expand its customer base to include hospital clients, diversifying revenue sources and strengthening market position[33]

Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) (股份代號：00512) 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 自願性公告 關於 2021 年及 2022 年年報之補充公告 茲提述遠大醫藥集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）分別於 2022 年 4 月 25 日及 2023 年 4 月 27 日刊發之 2021 年年報及 2022 年年報（「年報」）。 除另有定義外，本函件所用之詞彙與年報所界定者具有相同涵義。 | | | | 退休福利 | | | --- | --- | --- | --- | --- | | | 袍金 | 薪金及津貼 | 計劃供款 | 合計 | | | 港幣千元 | 港幣千元 | 港幣千元 | 港幣千元 | | 執行董事： | | | | | | 劉程煒先生（於二零二一年六 | | | | | | 月一日退任） | 21 ...

Financial Performance - The company's revenue for the first half of 2025/26 increased by approximately 21% to HKD 470 million, compared to HKD 389 million in the same period last year[6]. - Net profit for the period was HKD 47 million, a significant increase from HKD 3 million in the previous year, resulting in earnings per share of HKD 0.5644[5][18]. - Revenue from customer contracts for the six months ended September 30, 2025, was HKD 469,769,000, an increase of 20.8% compared to HKD 388,785,000 for the same period in 2024[39]. - Gross profit for the same period was HKD 89,026,000, representing a gross margin of 19.0%, up from HKD 58,439,000 in 2024[39]. - Operating profit increased significantly to HKD 63,542,000, compared to HKD 9,889,000 in the previous year, reflecting a substantial improvement in operational efficiency[39]. - The company reported a profit of HKD 47,411 thousand for the six months ended September 30, 2025, compared to HKD 3,237 thousand in the same period last year, reflecting a substantial increase[42]. Dividends and Shareholder Returns - The company declared an interim dividend of HKD 0.12 per share, compared to no dividend in the previous year[5]. - The company declared an interim dividend of HKD 0.12 per share for the period, compared to no dividend in 2024[63]. - Basic and diluted earnings per share for the period were HKD 56.44, a significant increase from HKD 3.85 in the previous year[39]. Financial Position - The net asset to debt ratio improved to 14% from 28% in the previous period, indicating a stronger financial position[5][23]. - The current ratio increased to 0.95 from 0.87, reflecting better liquidity management[5][20]. - Total assets reached HKD 935,630 thousand, an increase of 1.3% compared to HKD 921,078 thousand as of March 31, 2025[41]. - Total equity rose to HKD 527,065 thousand, up 9.9% from HKD 479,654 thousand[41]. - Total liabilities decreased to HKD 408,565 thousand from HKD 441,424 thousand, a reduction of 7.4%[41]. Cash Flow and Expenses - Cash and bank balances totaled approximately HKD 96 million, down from HKD 112 million, primarily due to operational cash flow and repayment of advances[21]. - Net cash generated from operating activities increased significantly to HKD 89,550 thousand, compared to HKD 42,665 thousand in the previous period, marking a growth of 109.8%[43]. - Administrative expenses remained stable at approximately HKD 25 million, while net financial costs decreased by about 41% to HKD 5 million due to lower interest rates[18]. - Total cost of sales and administrative expenses for the six months ended September 30, 2025, amounted to HKD 406,228,000, up 15% from HKD 353,948,000 in 2024[54]. Workforce and Employment - As of September 30, 2025, the company had 511 employees, an increase from 420 employees as of March 31, 2025, indicating growth in workforce[28]. Projects and Contracts - The total value of major contracts on hand is approximately HKD 630 million, down from HKD 961 million previously, with ongoing projects contributing to revenue[5][6]. - The Lantau Island project accounted for about 70% of the group's revenue during the period, with a contract value of approximately HKD 846 million[10][11]. - The company expects to start generating revenue from a new public housing development project in Yuen Long in the second half of the fiscal year[17]. Liabilities and Financial Obligations - The company has no significant contingent liabilities other than a performance guarantee of approximately HKD 29,000,000 related to a foundation engineering project[26]. - The company has pledged machinery and equipment with a net book value of approximately HKD 44,000,000 as collateral for long-term bank loans[27]. - The company’s borrowings decreased to HKD 171,762 thousand from HKD 167,140 thousand, indicating a slight increase of 2.4%[41]. - Trade payables increased to HKD 89,512 thousand as of September 30, 2025, compared to HKD 78,028 thousand as of March 31, 2025, reflecting a growth of 14.5%[67]. - Short-term bank loans rose to HKD 158,566 thousand as of September 30, 2025, up from HKD 148,016 thousand as of March 31, 2025, indicating an increase of 7.4%[67]. Management and Strategic Direction - The board believes that the appointment of Mr. Liu Zhenming as CEO will enhance the company's strategic direction in the competitive Hong Kong construction market[35].

Revenue Performance - For the six months ended September 30, 2025, the Group's total revenue decreased by approximately 3.4% to HK$173,151,000 from HK$179,187,000 in the corresponding period last year[17] - The decrease in revenue was primarily due to the completion of significant long-term contracts and a decline in demand for vessel chartering and related services[17] - Revenue from marine construction services increased due to improved construction progress on key projects during the Period[17] - The Group expects demand for vessel chartering services to diminish gradually as high-profile marine construction projects reach completion[11] - Revenue for the six months ended September 30, 2025, was HK$173,151,000, a decrease of 3% from HK$179,187,000 in the same period of 2024[125] - Revenue from vessel chartering and related services decreased to HK$52,176,000 from HK$75,995,000, representing a decline of approximately 31.4%[167] - Revenue from marine construction services increased significantly to HK$107,487,000 from HK$89,923,000, marking an increase of about 19.4%[167] Profitability - Gross profit increased by approximately 4.4%, from HK$48,564,000 for the corresponding period last year to HK$50,713,000 for the Period[23] - The gross profit margin increased by approximately 2.2 percentage points from approximately 27.1% for the corresponding period last year to approximately 29.3% for the Period[23] - Profit attributable to owners of the Company increased by approximately 35.4%, from HK$10,531,000 for the corresponding period last year to HK$14,255,000 for the Period[35] - Basic earnings per share attributable to owners of the Company increased from approximately HK1.05 cent for the corresponding period last year to approximately HK1.43 cent for the Period[40] - Total comprehensive income for the period was HK$20,445,000, up from HK$16,993,000, reflecting a growth of 20.5%[125] - Profit for the period attributable to owners of the Company was HK$14,255,000, representing a 35.5% increase compared to HK$10,531,000 in the previous year[125] Financial Position - The Group's net current assets increased from HK$167,793,000 as at 31 March 2025 to HK$183,164,000 as at 30 September 2025[38] - The current ratio increased from approximately 2.5 as at 31 March 2025 to approximately 2.7 as at 30 September 2025[38] - The gearing ratio decreased from 2.40% at 31 March 2025 to 2.16% at 30 September 2025[39] - The Group's trade and other receivables decreased from HK$84,756,000 as at 31 March 2025 to HK$80,495,000 as at 30 September 2025[37] - Non-current assets decreased to HK$148,145,000 from HK$158,235,000, a decline of 6.4%[126] - Current assets increased to HK$288,481,000, up from HK$282,270,000, showing a growth of 2.4%[126] - Current liabilities decreased to HK$105,317,000 from HK$114,477,000, a reduction of 8%[126] - Net current assets increased to HK$183,164,000 as of 30 September 2025, up from HK$167,793,000 at 31 March 2025, representing a growth of 9.2%[128] - Total assets less current liabilities rose to HK$331,309,000, compared to HK$326,028,000 at the end of March 2025, indicating a 1.0% increase[128] - Net assets reached HK$314,353,000, an increase of 2.5% from HK$307,828,000 as of 31 March 2025[128] Cash Flow - Net cash from operating activities was HK$19,964,000 for the six months ended 30 September 2025, a significant improvement from a cash outflow of HK$11,990,000 in the prior year[133] - Cash used in investing activities totaled HK$6,977,000, a decrease from cash inflow of HK$13,536,000 in the same period last year[133] - The Group reported a net cash used in financing activities of HK$17,258,000, an improvement from HK$28,880,000 in the previous year[133] - The net decrease in cash and cash equivalents for the six months ended 30 September 2025 was HK$4,271,000, compared to a decrease of HK$27,334,000 for the same period in 2024[134] - Cash and cash equivalents at the end of the period were HK$69,301,000, an increase from HK$49,243,000 at the end of the previous period[134] Corporate Governance - The Company is committed to high corporate governance standards to safeguard shareholder interests and enhance corporate value[114] - The Company has maintained compliance with the Corporate Governance Code, except for the separation of the roles of chairman and CEO[115] - The Audit Committee, comprising three independent non-executive Directors, reviewed the financial statements and internal controls for the period[118] Shareholder Information - As of September 30, 2025, the company has a total of 560,114,750 shares held by Kitling Investments (BVI) Limited, representing 56.00% of the shareholding[87] - Directors Wen Tsz Kit Bondy and Chan Sau Ling Amy each have an interest in the same 560,114,750 shares, also accounting for 56.00% of the shareholding[94] - The share capital of Kitling (BVI) is beneficially owned by Mr. Wen and Ms. Chan as to 70% and 30% respectively[95] - There were no other interests or short positions of the Directors in the shares or underlying shares of the Company as of September 30, 2025[89] - The Company was successfully listed on the Main Board of the Stock Exchange on 18 March 2019, with net proceeds from the listing amounting to approximately HK$65.6 million[110] - As of 30 September 2025, a total of HK$43.6 million of the net proceeds had been utilized according to the allocation set out in the Company's announcement[110] Segment Information - The Group's operating segments include vessel chartering, ship management, and marine construction services, focusing on resource allocation and performance assessment[144] - The segment profit for the vessel chartering services was HK$25,793,000, ship management services was HK$6,655,000, and marine construction services was HK$17,952,000, totaling HK$50,400,000[150] - The Group's inter-segment revenue was HK$10,406,000, with total segment revenues amounting to HK$173,151,000[150] Other Financial Information - The Group incurred no capital expenditure during the six months ended September 30, 2025, compared to HK$3,110,000 in 2024[57] - No significant investments, acquisitions, or disposals of subsidiaries were made during the period[53] - As of September 30, 2025, there were no significant capital commitments[55] - The Group has not been awarded any tenancy for the shipyard sites tendered, but will continue to seek suitable opportunities[113]